326 related articles for article (PubMed ID: 12611452)
1. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Claus EB; Stowe M; Carter D
Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Claus EB; Petruzella S; Matloff E; Carter D
JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
[TBL] [Abstract][Full Text] [Related]
3. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Hall MJ; Reid JE; Wenstrup RJ
Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
[TBL] [Abstract][Full Text] [Related]
5. Breast carcinoma in situ: risk factors and screening patterns.
Claus EB; Stowe M; Carter D
J Natl Cancer Inst; 2001 Dec; 93(23):1811-7. PubMed ID: 11734598
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Claus EB; Schildkraut J; Iversen ES; Berry D; Parmigiani G
J Natl Cancer Inst; 1998 Dec; 90(23):1824-9. PubMed ID: 9839523
[TBL] [Abstract][Full Text] [Related]
9. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
[TBL] [Abstract][Full Text] [Related]
12. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
15. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Malone KE; Daling JR; Neal C; Suter NM; O'Brien C; Cushing-Haugen K; Jonasdottir TJ; Thompson JD; Ostrander EA
Cancer; 2000 Mar; 88(6):1393-402. PubMed ID: 10717622
[TBL] [Abstract][Full Text] [Related]
16. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and the risk of ductal breast carcinoma in situ.
Claus EB; Stowe M; Carter D
Breast Cancer Res Treat; 2003 Sep; 81(2):129-36. PubMed ID: 14572155
[TBL] [Abstract][Full Text] [Related]
19. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
20. Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
